Jade Biosciences announces first participant dosed in first-in-human Phase 1 clinical trial of JADE201, a novel half-life extended Afucosylated anti-BAFF receptor monoclonal antibody
[출처/시간] Briefing.com - 4:17 PM ET, 05/26/2026 SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc., (JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the first participant has been dosed in a first-in-human Phase 1 clinical trial of JADE201. JADE201 is an investigational, half-life extended, afucosylated monocl
[출처/시간] Briefing.com - 4:17 PM ET, 05/26/2026
SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc., (JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the first participant has been dosed in a first-in-human Phase 1 clinical trial of JADE201. JADE201 is an investigational, half-life extended, afucosylated monoclonal antibody targeting the B cell activating factor receptor designed to deplete B cells through a dual mechanism of action: enhanced antibody effector function and BAFF signal blockade. The Company expects interim FIH data in 2027.Click here for full release.
당신의 반응은 무엇인가요?
좋아요
0
싫어요
0
사랑
0
재미있는
0
화난
0
슬프다
0
와우
0
